UBS Group
NKTR icon

UBS Group’s Nektar Therapeutics NKTR Stock Holding History

UBS Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-267
Closed -$50K – 8550
2015
Q2 		$50K Sell
267
-66
-20% -$11.4K ﹤0.01% 6008
2015
Q1 		$55K Buy
+333
New +$68.4K ﹤0.01% 5946

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's NKTR Position: Q2 2026 in Review

UBS Group increased its Nektar Therapeutics (NKTR) stake by 34% in Q2 2026, buying an estimated $7.92M and bringing the position to 428,400 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

UBS Group first reported a position in NKTR in Q4 2014 and has held it in 47 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • UBS Group held 428,400 shares of Nektar Therapeutics worth $29.9M as of Q2 2026.
  • UBS Group bought 108,228 Nektar Therapeutics shares in Q2 2026, an estimated $7.92M.
  • Nektar Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2266 holding.
  • UBS Group first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.